LOC – Talk Bio

Actionable Insights Powered by AI

The 5 Largest Biopharma Layoffs of Q1 2025: An Overview of Industry Restructuring

2 weeks ago talkbio0Tagged 2025, Biopharma layoffs, Drug Industry, Galapagos layoffs, Gilead, Industry, losses, Merck, Myers, Novartis, Q1 2025, restructuring, Squibb Layoffs, trends qualifier

Biopharma layoffs 2025, Novartis layoffs, Galapagos layoffs, Bristol Myers Squibb layoffs, Merck cuts, Gilead workforce reduction, Q1 2025 job cuts, biotech restructuring, pharmaceutical industry job losses, industry trends.

Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

3 months ago talkbio0Tagged Antidote, CAR-T, Catalent, decentralized, Duodote, Galapagos, Kindeva, Lymphoma, Non-Hodgkin, Manufacturing, Nerve Agents, NHL, Strategic National Stockpile

Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile

Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase

3 months ago talkbio0Tagged Bay Area, Biotechnology, Chinese biotechs, Greater, HKEX, IPOs, Kong, listing reforms, Listings

Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.

Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China

4 months ago talkbio0Tagged Aficamten, China, Cytokinetics, Dosage Forms, Heart, Hypertrophic Cardiomyopathy, sanofi

Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal

CARsgen and Galapagos Resume CAR-T Trials Without Restrictions

6 months ago talkbio0Tagged Cancer Therapeutic Procedure, CAR-T trials, CARsgen, Clinical Trials, Galapagos

CAR-T trials, CARsgen, Galapagos, cancer treatment, clinical trials

Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation

8 months ago talkbio0Tagged Control Groups, Corporate, Galapagos, Influence, investor, Undervaluation

Galapagos, investor influence, undervaluation, biotech, corporate control

Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network

8 months ago talkbio0Tagged Acquisition (action), Europe, Novartis, Pet Animal, Radiodiagnostic Manufacturing Network, Radiopharmaceuticals, Siemens Healthineers

Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals

Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case

9 months ago talkbio0Tagged bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CAR-T, Clinical Trials, Galapagos, GLPG5301, Multiple Myeloma, PAPILIO-1, Parkinsonian Disorders

Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301

Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts

9 months ago talkbio0Tagged Asia, business career, China, Kyowa Kirin, restructuring, Small-Molecule Discovery

Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals

Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case

9 months ago talkbio0Tagged BCMA-directed therapy, CAR-T, Cell Therapy, Clinical Trials, Enrollment, Galapagos, Multiple Myeloma, Parkinsonian Disorders

Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma